These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 27357182

  • 1. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N, Yamagishi SI, Bekki M, Kodama N, Nakamura T, Sugiyama Y, Oshige T, Kumashiro Y, Honda A, Tahara A, Igata S, Fukumoto Y.
    Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
    [Abstract] [Full Text] [Related]

  • 2. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI.
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [Abstract] [Full Text] [Related]

  • 3. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T.
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Nov 03; 15(1):150. PubMed ID: 27809848
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A, Tanaka A, Morimoto T, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Ueda S, Node K.
    Cardiovasc Diabetol; 2019 Nov 16; 18(1):158. PubMed ID: 31733647
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes.
    Kozlovski P, Bhosekar V, Foley JE.
    Vasc Health Risk Manag; 2017 Nov 16; 13():123-126. PubMed ID: 28408838
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
    Yano W, Inoue N, Ito S, Itou T, Yasumura M, Yoshinaka Y, Hagita S, Goto M, Nakagawa T, Inoue K, Tanabe S, Kaku K.
    J Diabetes Investig; 2017 Mar 16; 8(2):155-160. PubMed ID: 27860391
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM, Dutta D, Nagendra L, Sharma M, Patra S, Bhattacharya S.
    Medicine (Baltimore); 2024 Jul 12; 103(28):e38870. PubMed ID: 38996148
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE, Bhosekar V, Kawamori R.
    Vasc Health Risk Manag; 2016 Jul 12; 12():9-12. PubMed ID: 26855580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.